Otis Worldwide Free cash flow decreased by 50.8% to $380.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 143.6%, from $156.00M to $380.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -2.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $493.00M | $324.00M | $236.00M | $474.00M | $326.00M | $215.00M | $430.00M | $253.00M | $409.00M | $272.00M | $555.00M | $140.00M | $284.00M | $362.00M | $651.00M | $156.00M | $179.00M | $337.00M | $772.00M | $380.00M |
| QoQ Change | — | -34.3% | -27.2% | +100.8% | -31.2% | -34.0% | +100.0% | -41.2% | +61.7% | -33.5% | +104.0% | -74.8% | +102.9% | +27.5% | +79.8% | -76.0% | +14.7% | +88.3% | +129.1% | -50.8% |
| YoY Change | — | — | — | — | -33.9% | -33.6% | +82.2% | -46.6% | +25.5% | +26.5% | +29.1% | -44.7% | -30.6% | +33.1% | +17.3% | +11.4% | -37.0% | -6.9% | +18.6% | +143.6% |